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Comparison of Four High-Sensitivity Immunoradiometric Assays for
ITiyrotropin and Results of Preliminary Clinical Studies
IVlalachi J. McKenna, MD,* Earl Goad, BS,+ Mohini Pimputkar, MS,^ and
Carolyn S. Feldkamp, PhD^

New immunoradiometric assays (IRMAs) that detect low concentrations of thyroid-stimulating
hormone (TSH) have recently become available for routine diagnostic use. These new assays have the
putative advantage over conventional radioimmunoassay in that they can distinguish hyperthyroidism
from euthyroidism by thefindingofa serum TSH below the normal limit. In the present study we sought
to evaluate four of these kits according to analytical performance characteristics and clinical utility.
All IRMAs could detect TSH at a concentration substantially below the lower limit of normal and thus
effectively identify hyperthyroid samples. Although differences in the performance characteristics
were found, all assays were clearly superior to the conventional radioimmunoassay. It is
recommended that IRMAs for TSH be used as routine diagnostic tests for thyroid dysfunction. Their
full value in the assessment of hyperthyroidism and other thyroid disorders has yet to be determined.
(Henry Ford Hosp MedJ 1987:35:201-6)

F

unctional disorders of thyroid gland activity, both oversecretion and undersecretion, are readily detected by the
use of radioligand assays. In current clinical practice a diagnosis
of hyperthyroidism is most often confirmed by the finding of an
elevated free thyroxine index (FTI), which is the product of
serum total thyroxine and triodothyronine resin uptake. Hypothyroidism is identified by a low FTI, and an elevated thyroidstimulating hormone (TSH) level distinguishes primary disease
from hypothalamic-pituitary hypofunction. In circumstances
of clinical doubt, the TSH response to thyrotropin-releasing
tiormone (TRH) can clarify the diagnosis: being suppressed in
primary hyperthyroidism, hyperresponsive in primary hypothyroidism, and hyporesponsive in secondary hypothyroidism.
It has recently been suggested that the laboratory approach to
diagnosis of thyroid dysfunction should change with the introduction of immunoradiometric assays (IRMAs) that are of high
sensitivity (1,2). Their ability to detect TSH at much lower concentrations than standard radioimmunoassays (RIAs) means
'nat TSH in serum can be detected well below the reference
range for healthy persons, a limitation of all previously available
methods. Therefore, a single specimen of blood for measurenient of TSH by the IRMA technique should be an appropriate
screening test for states of both reduced and augmented TSH
secretion.
In the present study we sought to 1) compare the performance
characteristics of four IRMAs for TSH regarding sensitivity,
precision, and accuracy; 2) determine reference ranges; and
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3) evaluate the capability of these assays to distinguish hyperthyroidism from euthyroidism.

Methods
Assays
Four new high-sensitivity IRMA kits for TSH were evaluated (Table 1); NML TSHIRMA (Organon Teknika, Durham,
NC), Echoclonal TSH (Bio-Rad Laboratories, Hercules, CA),
MAGIC mab TSH (Ciba Coming, Medfield, MA), and Allegro
HSTSH (Nichols Institute Diagnostics, San Juan Capistrano,
CA). According to the test principle for IRMA, an excess of radioactively labeled antibody reacts with the full amount of unknown antigen. Two or more antibodies (at least one of which is
monoclonal) bind to different antigenic sites on the TSH molecule, resulting in an antibody-thyrotropin-antibody "sandwich"
(Fig 1). In contradistinction, in the RIA the unknown antigen
competes with radioactively labeled antigen for binding with a
limited quantity of antibody. This methodological difference, in
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Table 1
Immunoradiometric Assays

^^^j^)_*antip
Fig I—Schema depicting principle ofthe IRMA technique
whereby the TSH molecule is "sandwiched" between two antibodies, one binding to the a chain and the other (which is radiolabeled*) to the P chain.

Number of Antibodies
Monoclonal
Polyclonal

Assay
NML
Bio-Rad
Nichols
Coming

1
2*
2*
1

•Radiolabeled.

Assay
NML
Bio-Rad

Table 2
Least Detectable Dose of TSH
NML
Bio-Rad
Nichols
Coming

100,000

1*
0
1
1*

Separation
Method
Coated tube
Coated tube
Avidin-coaled bead
Magnetic

0.09
0.21
0.08
0.04

p.U/mL
p,U/mL
p,U/mL
|iU/mL

(CPM) of the zero standard from the average CPM of each standard. The standard curve of corrected CPM (the "y" axis) versus the known concentration of the TSH standards (the "x" axis)
was calculated according to a power fit using a programmable
calculator (HP4I CX) (Fig 2). The regression equation was then
used to determine TSH concentrations in unknown analytes
from their corrected CRMs.

Nichols t

Comingt

*The number (
\ariation.
tAverage of f<

Assay
Nichols

too

0.1

0.5

1.0

5.0 10.0

50.0

serum TSH pU/ml

Fig 2—Example ofan IRMA standard curve from a Nichols
assay. The very low standards (O.I and 0.25 [xU/mL) were
obtained by dilution of the 0.5 standard with zero standard.
The power fit gives a linear relationship between O.I and 100
[xU/mL.

addition to the use of monoclonal antibodies, permits greater
sensitivity in the detection of TSH by IRMAs compared to conventional RIAs. Each of the four IRMAs were similar in that one
or more monoclonal antibodies were employed and in two
instances were radiolabeled (Table I). Separation of antibodybound antigen from free antigen was achieved by a variety of
techniques: use of antibody-coated tubes (NML and Bio-Rad),
binding of antibody coupled with biotin to avidin-coated beads
(Nichols), and magnetic separation for which paramagnetic particles are covalently bound to one antibody (Coming). Assays
were of similar duration with each requiring one or more wash
steps. Samples were also measured by our standard RIA (Leeco,
Southfield, MI).
Foreach assay, standards were analyzed in duplicate. In addition, the low standard was diluted with zero standard to give
concentrations below 0.15 ixU/mL. Adjustment for nonspecific
binding was made by subtraction of the mean counts per minute
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Performance characteristics
Sensitivity was evaluated by measuring the precision of multiple samples of the zero standard (n = 10) in an assay. The minimal detectable dose was defined as the concentration exceeding
the zero standard at the 95% confidence level. Intraassay precision was evaluated using pooled sera at four different levels of
concentrations, including a hyperthyroid pool for the very low
end of the standard curve (FTI = 20.5 |JLg/dL). Interassay precision was evaluated for the Coming and Nichols assays. Accuracy at low levels of TSH concentration was analyzed by
means of dilution and recovery studies. A precision profile was
obtained for the Coming and Nichols assays by calculating the
median of the coefficient of variation for duplicate determinations ranging from the limit of detectability to 10 p,IU/niL. The
Nichols and Coming assays were selected at an early stage ofthe
evaluation for more detailed analysis in view of preliminary
findings and convenience in the laboratory.

Coming

All data w
ear regressi
method, the

Performan*
The minir
"all but the
(Table 2). T
'concentratio
^^plesfor'ientofvarii
Clinical studies
*ery low TS
Nineteen clinical samples were analyzed in all four assays , value foi
Samples were randomly selected from laboratory specimens on *le dose. Ii
the basis of either hyperthyroxinemia (an FTI above the 95 c '"d Nichols
reference range, ie, > 11.5; n = 9) or euthyroxinemia (an Fl horning ant
result within 1 SD of the mean for healthy adults; n = l")' ladiratl.Oi
A larger number of clinical samples (n = 28) obtained fro"" ^""ngTSH;
subjects with hyperthyroidism, either due to Graves' disease ( 1 '°^cred app
= 11) or excessive thyroid hormone supplementation (n =
''^"Itofabo
were analyzed in both the Coming and Nichols assays. The log^ "Matrix diff
mean ± SDof the FTI was 16.6 ± 1.3 |xg/dL, ranging from 1'^
standar
to 31.8 M-g/dL. In addition, samples from healthy, unmedica' >entrati<
adults (28 women, 27 men) were measured in the Cor^m^ y^ad, lo
Nichols, and Leeco assays. A further 43 miscellaneous sampl^' ^Itswith
were measured in both the Coming and Nichols assays.
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Table 5
Dilution Studies at Low Concentration of TSH

Table 3
Intraassay Precision
nation
;thod
ed mbe
ed tube
coated bead
gnetic

Number per
Assay

Mean Value
(p,U/mL)

2
2
2
3
4
4
4

1.2
6.4
16.3
1.7
10.7
29.6
1.7
10.8
30.4
1.2
9.1
29.6

(Low; High)*

4
4
4
4

f each stantan" axis) verle "x" axis)
ixis)
igrammable
able I
on was then
then
vn analytes

Bio-Rad

0.8
3.3
}.><
,1.3

Nichols

2.6
6.-3
3..S
3.7

Coming

Table 4
Interassay Precision
Number of
Assays

Mean Value
(M-U/mL)

Coefficient of
Variation (%)

4
4

1.7
10.8
30.4
1.2
9.1
29.6

4.6
6.3
3.8
1,7
5.2

4
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Dilution
Factor
undiluted
1:2
1:4
undiluted
1:2
1:4
undiluted
1:2
1:4
undiluted
1:2
1:4

Assay
NML

% Recovery
B/A X 100

—

—

0.32
0.11

123
8.S

—

—

0.64
0.39

86
105

—

—

0.56
0.31

108
119

—

—

0.28
0.13

67
62

Table 6

Nichols

1 four assays,
specimens on
bove the 95%
lemia (an FTI
llts; n = lO).
ibtained froffl
ves' disease (n
tion (n = 17)'
says. The logging from 11'^
r, unmedicated
the Corning,
neous sample'
assays.

(1.06; 1.40)
(6.45; 6.39)
(15.5; 17.1)

•The number of samples from the NML assay was insufficient to calculate a coefficient of
variation.
tAverage of four different assays.

Assay

ion of multiy. The miniin exceeding
lassay precient levels of
the very low
terassay preassays. Acanalyzed by
n profile was
ilculating the
;e determinajiIU/mL. The
ly stage of the
•preliminary

—
—
—

Measured
Value
B
((jtU/mL)

Expected
Value
A
(p,U/mL)
0.51
0.26
0.13
1.48
0.74
0.37
1.03
0.52
0.26
0.84
0.42
0.21

Coefficient of
Variation (%)

Coming

4
4
4

Assay
NML
Bio-Rad
Nichols
Coming

All data were log-transformed before statistical analysis. Linear regression analysis was performed by the least squares
method, thereby giving a powerfitfor the log-transformed data.

Added
A
(p,U/mL)
0.20
0.74
0.20
1.00
0.20
0.65
0.20
0.80

Base
B
(|iU/mL)
0.19
0.19
0.21
0.21
0.02
0.02
0.09
0.09

Measured
C
(p.U/mL)
0.35
0.88
0.27
1.62
0.24
0.64
0.28
0.62

% Recovery
(C-B)/AxI0O
80
93
30
141
IIO
95
95
66

18
16
14

Results
Performance characteristics
The minimal detectable dose of TSH was less than 0.1 |xU/mL
in all but the Bio-Rad assay which gave a result of 0.21 ixU/mL
(Table 2). The intraassay precision at low, medium, and high
concentrations of TSH was similar in all assays; the number of
samples for the NML assay was insufficient to calculate a coefficient of variation (Table 3). Reproducibility of measurements at
very low TSH concentrations could not be detennined because
the value for the hyperthyroid pool was below the least detectable dose. Interassay variation was similar in both the Coming
Nichols assays (Table 4). Analysis of precision profiles for
Coming and Nichols assays showed a similar pattern with a
"adir at 1.0 ixU/mL (Fig 3). Regarding the dilution studies measuring TSH at concentrations below 0.5 p,U/mL, the percent recovered approximated 100% except for Coming which gave a
Ksult of about 65% (Table 5). Low recoveries were attributed to
^matrix difference between the sample and the specially treated
^0 standard used as diluent. Recovery of added TSH at a low
'Concentration of < 1.0 |xU/mL yielded increased results with
^io-Rad, low values with NML and Coming, and satisfactory
results with Nichols (Table 6). Recovery at higher concentra'ons gave good results for all assays.
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%CV

10
8
6
4
2
0
0.2

0.6

1.0

1.4

2.0

10.0

TSH \1 U/ml

Fig 3—Precision profile analysis for Nichols (A) and Corning
(o) assays.

Clinical studies
The 19 clinical samples measured in the four assays gave
similar results. Hyperthyroxinemic samples were lower than euthyroxinemic samples; this was not observed with the RIA (Fig
4). There was good agreement between all assays with correlation coefficients exceeding 0.95 (Table 7). The slope oftiieregression line for Coming and Nichols was closest to the line of
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Nichols

NML

Corning

Blo-rad

Assays

3
3.

X

NML
NML
NML
Bio-Rad
Bio-Rad
Coming

I-

E

1-

vs
vs
vs
vs
vs
vs

y
Bio-Rad
Nichols
Coming
Coming
Nichols
Nichols

Correlation
Coefficient
(r)
0.88
0.86
0.89
0.98
0.98
0.97

Regression equation according to a [
has a slope of 1.0 and intercept of 1.0.

undeteclable^.

Fig 4—Serum TSH values in nine hyperthyroxinemic (A ) and
ten euthyroxinemic (*) subjects.

30.0

Slope
b
1.47
1.11
1.07
0.77
0.78
1.02

Intercept
a
1.46
1.20
1.18
0.80
0.84

X

sn

«

o
.c
o

z

0.2

0.5

1.0

Coming

5.0 10.0

30.0

serum TSH pU/ml

Fig 5—Comparison of results obtained by Corning and Nichols
assays. The average results of quality control specimens at three
concentrations are represented by triangles.

equivalence at 1.02. In an even larger sample (n = 71), this close
relation was confirmed (Fig 5). The log-mean value (and 95%
reference range) for a group of 55 healthy, nonmedicated adults
with Coming was 0.74 |xU/mL (0.19 to 2.79 |xU/mL) and with
Nichols was 1.78 p,U/mL (0.59 to 5.21 [xU/mL) (Fig 6). The
findings were similar to the manufacturers' ranges of 0.29 to 5.11
p,U/mL (Coming) and 0.9 to 4.6 |xU/mL (Nichols). No sex difference was observed with both Corning and Nichols assays.
However, values were significantly higher in women than men
with the RIA, suggesting reduced specificity in women possibly
due to higher semm gonadotrophins that could cross-react with
the TSH antibody. All 28 samples from hyperthyroid subjects

Henry Ford Hosp Med J—Vol 35, No 4, 1987
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0.5

l.u
'. The line of equivalence

were below reference ranges for both Coming and Nichols assays. In contrast, only one of 23 of the same samples was below
the euthyroid range for the RIA (Fig 7).

Discussion

E
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Table 7
Comparison of the Four Assays Using

RIA

This study demonstrates that TSH levels can be detected at
low concentration by all the IRMAs selected for comparison.
Unlike a conventional RIA, the IRMAs could readily detect
TSH below the lower limit of the normal range. In so doing, the
new assays can distinguish hyperthyroidism from euthyroidism.
Differences in the performance characteristics between the
four assays were observed. Sensitivity results, although variable, were comparable in that the limit of detectability in each
case was nearly tenfold lower than the bottom of the expected
normal range. Differences in accuracy, reflected in both the parallelism and recovery studies, were also documented at low TSH
concentrations (Tables 5 and 6). Again, thesefindingsare probably of little clinical relevance. Of greater importance is that all
four assays distinguished hyperthyroxinemic samples from euthyroxinemic ones satisfactorily and to the same degree (Fig 4).
In more detailed clinical studies with Corning and Nichols
assays, it was possible in all instances to identify cases of hyperthyroidism by virtue of a single TSH measurement. Indeed, values were markedly suppressed below the euthyroid range (Fig
7). This is in accordance with other published reports (1,3-7).
Though not the focus of this report, IRMAs can also measure
TSH accurately in the euthyroid and hypothyroid ranges. However, unlike RIAs, IRMAs are theoretically subject to errof
at very high levels as a consequence of the so-called "hook
phenomenon (8). The high-dose hook effect may occur when
the analyte concentration approximates antibody concentration. An excessive quantity of antigen binds to a single antibody; these incomplete complexes do not separate with the anObody-antigen-antibody complexes. Thus, counting rats*
decrease inversely proportional to the quantity of analyte. ThJ^
phenomenon occurs only at concentrations exceeding 100 ^
mL; thus, very high levels of TSH may be underestimated. Tb'*
aberrancy is probably of quantitative rather than qualitative sig
nificance: a TSH value above 100 p,U/mL is rare and usually ^
sociated with florid clinical signs of hypothyroidism. '^^/^
there is not a single report of this phenomenon eventuating
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Fig 6—Serum TSH values in healthy adults including women
(9) and men (A). The mean ± 2 SD is represented by horizontal
lines. Expected 95% ranges are indicated by vertical lines. The Fig 7—Serum TSH values in hyperthyroid subjects plotted with
RIA gave significantly higher values in women compared to men regard to the 95% reference ranges (represented by the shaded
(p< 0.005).
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en-oneous diagnosis. If necessary, very high TSH may be quantified by measuring appropriately diluted samples.
Another potential impediment to the routine use of IRMAs is
the method of calculating the standard curve and data reduction.
Methods for computing RIAs, such as log-logit used in our laboratory, are not reliable for IRMAs. Nonetheless, appropriate
computerization enables rapid analysis while also incorporating
quality control features. In the future, the IRMA technique for
measuring TSH will replace conventional RIAs for all circumstances of use in the clinical radioligand laboratory. IRMAs
have a superior capacity for differentiating abnormal from normal values at no greater cost or technical burden.
The impact of IRMAs on clinical practice has yet to be ascertained, but they have the potential to alter the approach to biochemical interpretation of thyroid dysfunction. A number of
advantages have already been uncovered. First, it is possible to
detect situations of suppressed TSH secretion with a single
blood sample. IRMAs may be more sensitive in identifying hyperthyroidism than is a single measurement of either the FTI,
T3, or the free thyroid hormones (1). Of course, a low TSH cannot, and should not, be interpreted in isolation: it could be associated with high thyroid hormone levels, normal levels (ie,
autonomous thyroid function), or with low levels as in central
1 a single anti- liypothyroidism (9) and nonthyroidal illness (10). Second,
will likely replace the use of TRH stimulation testing
2 with the antiounting rates *o confirm dubious cases of hyperthyroidism. Nonetheless, in
f analyte. This situations where it is necessary to determine the adequacy of
eding 100 p-U' suppressive therapy with thyroid hormone TRH testing, using
sstimated. This "le IRMA rather than the RIA should provide additional inqualitative sig' formation (11). Third, high-sensitivity IRMAs have assisted in
^lucidating the chronobiology of TSH in health and disease
and usually
idism. Asye'' E P.12,13). In healthy subjects, the secretion of TSH follows a
entuatingin^ *Umal pattern: there is a nocturnal surge and a midday nadir
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The secretion happens in a pulsatile rather than a continuous
manner (12).
Some investigators have suggested that IRMAs be used as the
initial screening test for thyroid dysfunction (1,7). This idea is a
radical departure, not only in the testing schedule but also in the
philosophy of testing, since this would be a venture into consultative reporting. This new "modus operandi" would entail an
initial TSH determination. Wayward results, both above and below a previously defined range, would dictate the need for measurement of semm thyroid hormones and in the process give a
biochemical diagnosis. The cutoff limits that proscribe further
studies are cmcial to the utility of this approach. A narrow limit
leads to unnecessary testing and expense, whereas a broad limit
may lead to misdiagnosis. It is also not yet certain if there is
a "gray" zone of TSH values comprised of an overlap between
euthyroid and hyperthyroid samples near the lower limit of
the normal range. There was none evident in our studies (Fig
7). However, one rare exception to this is pituitary-dependent
hyperthyroidism when the TSH level can be normal (14). Use of
the IRMA as a screening procedure has some promise, but it
does need further study and the understanding thatfindingsmust
be judged in the light of clinical opinion.
In conclusion, new IRMAs detect TSH at very low levels and
thus readily distinguish hyperthyroidism from euthyroidism.
They should replace conventional RIAs for routine use. Their
full value and impact in clinical practice has yet to be elucidated.
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